Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSCEND WORLD: JCAR017 in Aggressive B-cell Non-Hodgkin Lymphoma
jRCT1080224068Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 2, open-label, single-arm trial of lisocabtagene maraleucel in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 2 more, sponsored by Bristol Myers Squibb. Primary endpoints: Primary efficacy and Primary safety. Started Sep 2018; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on jRCT1080224068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224068.